Company Overview of PanOptica, Inc.
PanOptica, Inc., a biopharmaceutical company, is engaged in licensing and developing a portfolio of exciting and innovative therapeutics for major ophthalmic disease. The company offers PAN-90806, a small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy. It serves pharmaceutical companies. The company was founded in 2009 and is based in Bernardsville, New Jersey.
150 Morristown Road
Bernardsville, NJ 07924-2626
Founded in 2009
Key Executives for PanOptica, Inc.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
May 27, 2016
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact PanOptica, Inc., please visit panopticapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.